Keywords: dosing, begins, ph, iii, hematide, study, biopharmaceutical

Dosing begins in Ph III Hematide study

Article | 22 October 2007

Print This

US biopharmaceutical firm Affymax and Japanese drug maker Takeda say that dosing has begun in a Phase III clinical trial ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in